Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Pollard

Showing results (941-950 of 992) with videos related to

Pageof 100
Sort By:
Vaccine|May 6, 2023
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)Anthonet L Koen, Alane Izu, Vicky Baillie, et al.
Cell Metabolism|March 13, 2012
Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathwayHouman Ashrafian, Gabor Czibik, Mohamed Bellahcene, et al.
Cell Reports|December 31, 2022
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75Jiandong Huo, Aiste Dijokaite-Guraliuc, Chang Liu, et al.
The Lancet. Infectious Diseases|October 23, 2022
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trialShabir A Madhi, Gaurav Kwatra, Simone I Richardson, et al.
American Journal of Human Genetics|August 25, 2022
Variation in CFHR3 determines susceptibility to meningococcal disease by controlling factor H concentrationsVikrant Kumar, Richard B Pouw, Matias I Autio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2023
Raising AWaRe-ness of Antimicrobial Stewardship Challenges in Pediatric Emergency Care: Results from the PERFORM Study Assessing Consistency and Appropriateness of Antibiotic Prescribing Across EuropeLaura Kolberg, Aakash Khanijau, Fabian J S van der Velden, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2018
Incomplete penetrance for isolated congenital asplenia in humans with mutations in translated and untranslated <i>RPSA</i> exonsAlexandre Bolze, Bertrand Boisson, Barbara Bosch, et al.
The Lancet. Infectious Diseases|March 22, 2026
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trialsSanjeev M Bijukchhe, Natalie G Marchevsky, Freddie Kibengo, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Pageof 100

Showing results (941-950 of 992) with videos related to

Sort By:
Pageof 100
Vaccine|May 6, 2023
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)Anthonet L Koen, Alane Izu, Vicky Baillie, et al.
Cell Metabolism|March 13, 2012
Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathwayHouman Ashrafian, Gabor Czibik, Mohamed Bellahcene, et al.
Cell Reports|December 31, 2022
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75Jiandong Huo, Aiste Dijokaite-Guraliuc, Chang Liu, et al.
The Lancet. Infectious Diseases|October 23, 2022
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trialShabir A Madhi, Gaurav Kwatra, Simone I Richardson, et al.
American Journal of Human Genetics|August 25, 2022
Variation in CFHR3 determines susceptibility to meningococcal disease by controlling factor H concentrationsVikrant Kumar, Richard B Pouw, Matias I Autio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 11, 2023
Raising AWaRe-ness of Antimicrobial Stewardship Challenges in Pediatric Emergency Care: Results from the PERFORM Study Assessing Consistency and Appropriateness of Antibiotic Prescribing Across EuropeLaura Kolberg, Aakash Khanijau, Fabian J S van der Velden, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2018
Incomplete penetrance for isolated congenital asplenia in humans with mutations in translated and untranslated <i>RPSA</i> exonsAlexandre Bolze, Bertrand Boisson, Barbara Bosch, et al.
The Lancet. Infectious Diseases|March 22, 2026
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trialsSanjeev M Bijukchhe, Natalie G Marchevsky, Freddie Kibengo, et al.
Clinical and Experimental Immunology|February 2, 2023
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trialsMerryn Voysey, Amy Flaxman, Jeremy Aboagye, et al.
Pageof 100